Transitional type circulating tumor cells predict systemic recurrence and benefit of adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: long-term outcomes of the CLUSTER trial

Key Points

• Transitional circulating tumor cells effectively predict systemic recurrence after pancreatic cancer surgery.
• Findings suggest that patients with identified circulating tumor cells may benefit from adjuvant chemotherapy.
• The CLUSTER trial provides long-term outcome data supporting the role of circulating tumor cells in treatment decisions.
• This analysis underscores the importance of evaluating circulating tumor cells for personalized cancer therapy.